c-Abl Inhibition Exerts Symptomatic Antiparkinsonian Effects Through a Striatal Postsynaptic Mechanism
Parkinson's disease (PD) is caused by a progressive degeneration of nigral dopaminergic cells leading to striatal dopamine deficiency. From the perspective of antiparkinsonian drug mechanisms, pharmacologic treatment of PD can be divided into symptomatic and disease-modifying (neuroprotective)...
Saved in:
Main Authors: | Yu Zhou (Author), Yukio Yamamura (Author), Masatoshi Ogawa (Author), Ryosuke Tsuji (Author), Koichiro Tsuchiya (Author), Jiro Kasahara (Author), Satoshi Goto (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2018-11-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Inhibitory Effects of Antiparkinsonian Drugs and Caspase Inhibitors in a Parkinsonian Flatworm Model
by: Yoshihisa Kitamura, et al.
Published: (2003) -
Postsynaptic density protein 95 in the striosome and matrix compartments of the human neostriatum.
by: Ryoma eMorigaki, et al.
Published: (2015) -
Importance of Nanoparticles for the Delivery of Antiparkinsonian Drugs
by: Sara Silva, et al.
Published: (2021) -
Morphology regulation in vascular endothelial cells
by: Kiyomi Tsuji-Tamura, et al.
Published: (2018) -
PHARMACOKINETIC STUDIES OF NEW ANTIPARKINSONIAN DRUG RAPITALAM
by: Natalya Avdeeva, et al.
Published: (2016)